Kymera Therapeutics, Inc.
KYMR
NASDAQ·Healthcare·Biotechnology·Mkt cap $9.8B
$118.63
▼ -0.35%
P/E
-36.50
Mkt Cap
$9.8B
52-Wk Range
$40.10–$130.05
52-Week Range
$40.10 - $130.05
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 174.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary targeted protein degradation platform enabling selective elimination of disease-causing proteins
- First-mover advantage in PROTAC and E3 ligase-based therapeutic modality with multiple clinical programs
- Ability to target previously undruggable proteins using the body's natural protein disposal mechanisms
- Diversified pipeline across high-value therapeutic areas with significant unmet medical needs
Bear Case
1 risk
- Above-average volatility (beta 2.0).
Growth
Stable outlook
Clinical trial progression and regulatory milestones for IRAK4, IRAKIMiD, STAT3, and MDM2 programs
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+62.0% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying KYMR right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 29, 2026
AUG 5, 2026
Reported EPS of -$0.62 vs -$0.71 consensus (+13.0% surprise). Revenue of $65.0M vs $32.8M expected (+98.3%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+13.0%
Revenue trend · last 8Q
—
-85%
+115%
-55%
-26%
-61%
+55%
+466%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$3.7M
$7.4M
$22.1M
$11.5M
$2.8M
$2.9M
$34.4M
$65.0M
Margins · last 8Q
Gross
100.0%
Operating
-116.3%
Profit
-94.2%
Wall Street consensus
7 analysts · 71% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
71%
Hold
29%
Sell
0%
Median Price Target
$136.00
▲ +14.6% vs $118.63
Latest: Guggenheim · Aug 31, 2026
1 analyst covering
vs Industry
How KYMR stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related